The patient with comorbid depression and anxiety: The unmet need

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 6, 1999, Pages 20-24

  Bakish, David ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BUSPIRONE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; LORAZEPAM; NEFAZODONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; COMORBIDITY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; PATIENT CARE; PRIORITY JOURNAL; SUICIDE; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME;

EID: 0032923816     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8, sec 2):8-11
2. Fawcett J. Suicide risk factors in depressive disorders and in panic disorder. J Clin Psychiatry 1992;53(suppl 3):9-13
3. Regier DA, Boyd JH, Burke JD, et al. One-month prevalence of mental disorders in the US: based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988;45:977-986
4. Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry 1991;148:1512-1517
5. Fawcett J, Scheftner WA, Fogg L, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry 1990;147:1189-1194
6. Vollrath M, Angst J. Outcome of panic and depression in a seven-year follow-up: results of the Zurich study. Acta Psychiatr Scand 1989;80:591-596
7. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355-364
8. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depression Anxiety 1997;4:160-168
9. Beasley CM, Sayler ME, Bosomworth JC, et al. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991;11:166-174
10. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. J Clin Psychiatry 1992;53(suppl 2): 44-47
11. Kasper S, Moller H-J, Montgomery SA, et al. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine and imipramine. Int Clin Psychopharmacol 1995;9 (suppl 4):3-12
12. Moon CAL, Jago W, Wood K, et al. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice. J Psychopharmacol 1994;8:171-176
13. Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996;57(suppl 2):10-14
14. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998;18:136-144
15. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:50-58
16. Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Canadian Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999; 60:22-28
17. Haskins JT, Aguiar L, Pallay A, et al. for the Venlafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
18. Haskins JT, Rudolph R, Aguiar L, et al. for the Venlafaxine XR 214 Study Group. Double-blind, placebo-/comparator-controlled study of once daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
19. Haskins JT, Rudolph R, Aguiar L, et al. for the Venlafaxine XR 218 Study Group. Venlafaxine XR is an efficacious short-and long-term treatment for generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropsychopharmacology; Oct 31-Nov 4, 1998; Paris, France
20. Lecrubier Y, Moon CAL, Schifano F, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997;95:485-493
21. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19
22. Rickels K, Downing R, Schweizer E. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884-895
23. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982;43(12, sec 2):81-86
24. Casacalenda N, Boulenger JP. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications. Can J Psychiatry 1998;43:722-730
25. Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987;48(suppl 12):3-6
26. Sussman N. How to manage anxious patients who are depressed. J Clin Psychiatry 1993;54(suppl 5):8-16
27. Nutt D. Management of patients with depression associated with anxiety symptoms. J Clin Psychiatry 1997;58(suppl 8):11-16
28. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450
29. Johnson MR, Emmanuel N, Crawford M, et al. Treatment of generalized anxiety disorder with venlafaxine: a series of 11 cases. J Clin Psychopharmacol 1998;18:418-419